Dengue infection patients and healthy volunteer who are 18-50 years old dengue infection lipopolysaccharide intestinal permeability cytokines
Conditions
Interventions
Participants diagnosed with dengue infection (by dengue antigen NS1 or PCR for dengue virus) with or without warning signs, fulfilling World Health Organization criteria and in-patient treatment.,No p
Diagnostic,Diagnostic
Dengue infection group,Healthy volunteer group
Sponsors
Department of Clinical Tropical Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Participants diagnosed with dengue (by dengue antigen NS1 or PCR for dengue virus) with or without warning signs, fulfilling World Health Organization criteria and in-patient treatment, 2. No previous diagnosed dengue fever (by taking history), 3. Age 18-50 years old, 4. Normal consciousness without significant fatigue or dehydration, 5. No known any medical illness, no current medication taking (except acetaminophen will be allowed in patients with dengue infection group only), 6. Able to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Diagnosis of severe dengue infection, fulfilling World Health Organization criteria. Severe dengue infection is a potentially fatal complication, due to severe plasma leaking, severe fluid accumulation, respiratory distress, severe bleeding, or organ impairment, 2. Presence of comorbidities (e.g. pneumonia, diarrhea, diabetes, other local or systemic infections, cardiovascular or cerebrovascular or renovascular comorbidities, etc.) at time of admission, 3. Recent use of medication (except acetaminophen will be allowed in patients with dengue infection group only) or over the counter medication, prebiotic, probiotic or vitamin supplements, 4. History of gastrointestinal surgery, 5. Family history of inflammatory/irritable bowel syndrome, 6. Known to hypersensitivity reaction to mannitol and/or lactulose, 7. Presence of alcohol intake or substance misuse, 8. Pregnancy, 9. During menstruation period, 10. Non-Thai speaking participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intestinal permeability Day +1 after admission and Day+7 of fever onset Urinary lactulose-mannitol ratio | — |
Secondary
| Measure | Time frame |
|---|---|
| Intestinal damage and inflammation Day +1 after admission and Day+7 of fever onset Serum concentrations of human intestinal fatty acid binding protein (I-FABP); serum calprotectin; serum beta-D-glucan level,Blood microbiome Day +1 after admission and Day+7 of fever onset 16S rDNA high-throughput sequencing,Endotoxinemia Day +1 after admission and Day+7 of fever onset Endotoxin activity assay,Cytokine levels Day +1 after admission and Day+7 of fever onset Interleukin (IL)-1beta, IL-6, IL-8, tumor necrosis factor (TNF)-alpha, and CRP,Immune profiling Day +1 after admission and Day+7 of fever onset Direct immune profiling assay | — |
Countries
Thailand
Contacts
Public ContactWiwat Chancharoenthana
Mahidol University
Outcome results
None listed